Human immunodeficiency virus (HIV) II infection category B1
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Activity of human immunodeficiency virus type 1 promoter/TAR regions and tat1 genes derived from individuals with different rates of disease progression.
|
9191845 |
1997 |
Lymphoma, Follicular
|
0.010 |
Biomarker
|
disease |
BEFREE |
A spontaneously EBV transformed follicular lymphoma (FL) cell line, Tat-1, was established from the lymph node biopsy specimen of a patient with B cell FL, grade 1 in transformation to high grade disease.
|
11840295 |
2002 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality.
|
12809927 |
2003 |
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.
|
12783972 |
2003 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality.
|
12809927 |
2003 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer.
|
15651064 |
2005 |
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer.
|
15651064 |
2005 |
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer.
|
15651064 |
2005 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The RNA expression of PAX5 was evaluated with reverse transcriptase polymerase chain reaction in the tumor tissue of 75 patients with stage TaT1 bladder cancer treated with transurethral resection.
|
16566978 |
2006 |
Transitional cell carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder.
|
16566978 |
2006 |
nervous system disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
Together, these results demonstrate that the neurotoxic epitope of Tat(1-72) is different from the epitope that is indirectly neurotoxic following production of TNF-alpha from immune cells, and suggest that therapeutic interventions against TNF-alpha might be beneficial against HIV-1 associated neurological disorders.
|
17451964 |
2007 |
Low T3 Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We examined the role of TH transporters monocarboxylate transporter 8 (MCT8, also known as SLC16A2) and MCT10 in the pathogenesis of the low T(3) syndrome in prolonged critical illness.
|
19439506 |
2009 |
Serum albumin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study identifies multiple loci influencing human serum metabolite levels.
|
22286219 |
2012 |
Malignant neoplasm of urinary bladder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Focusing on patients with TaT1 non-muscle invasive BCa, BCL2L12 expression levels were correlated with higher recurrence rate at the first follow-up cystoscopy and were unveiled to be an independent unfavorable predictor of patients' short-term recurrence following transurethral resection.
|
23790536 |
2014 |
Bladder Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Focusing on patients with TaT1 non-muscle invasive BCa, BCL2L12 expression levels were correlated with higher recurrence rate at the first follow-up cystoscopy and were unveiled to be an independent unfavorable predictor of patients' short-term recurrence following transurethral resection.
|
23790536 |
2014 |
Drug habituation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Tat1-86 induced developmental neurotoxic effects, as witnessed by delays in eye opening, delays in early reflex development and alterations in prepulse inhibition (PPI) and between-session habituation of locomotor activity.
|
25285887 |
2014 |
Seizures
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Overall, the neurotoxic profile of Tat1-86 appeared more profound in the developing nervous system in vivo relative to that seen with the first exon encoded Tat1-72 (Fitting et al., 2008b), as noted on measures of eye opening, righting reflex, and PPI.
|
25285887 |
2014 |
Carcinoma of bladder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Focusing on patients with TaT1 non-muscle invasive BCa, BCL2L12 expression levels were correlated with higher recurrence rate at the first follow-up cystoscopy and were unveiled to be an independent unfavorable predictor of patients' short-term recurrence following transurethral resection.
|
23790536 |
2014 |
Amino acids measurement
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide association study identifies novel genetic variants contributing to variation in blood metabolite levels.
|
26068415 |
2015 |
Amino acids measurement
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA.
|
27005778 |
2016 |
Protein measurement
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA.
|
27005778 |
2016 |
Mean Corpuscular Volume (result)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thirty-nine patients with depression were randomly assigned to immediate MCT (10 sessions) or a 10-week wait list period (WL).
|
28174547 |
2017 |
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thirty-nine patients with depression were randomly assigned to immediate MCT (10 sessions) or a 10-week wait list period (WL).
|
28174547 |
2017 |